Taken together, our preclinical data suggest that the combination strategy of trametinib plus anlotinib synergistically induces antitumor activity in KRAS-mutant NSCLC, potentially via the MEK/RTK-IGFBP2-RTK signaling loop. The gene discussed is IGFBP2; the disease is non-small cell lung carcinoma.